Related Experiment Video
Updated: Mar 2, 2026

Assay to Measure Nucleocytoplasmic Transport in Real Time within Motor Neuron-like NSC-34 Cells
Published on: May 16, 2017
Alzheimer's Disease and ncRNAs
Rotem Maoz1, Benjamin P Garfinkel1, Hermona Soreq2
1The Edmond and Lily Safra Center of Brain Science, The Hebrew University of Jerusalem, Jerusalem, 9190401, Israel.
Abstract:
Alzheimer's disease is a devastating neurodegenerative disorder affecting a significant portion of the world's rapidly growing aging population. In spite of its prevalence, the etiology of the disease is still poorly understood, and effective therapy is all but unavailable. Over the past decade, noncoding RNA, including microRNA (miRNA), has emerged as a major class of regulatory molecules involved in virtually all physiological and disease states. The specificity provided by miRNA sequence complementarity, together with the ability of these molecules to regulate complex networks of genes, has made them exciting novel targets for therapeutic agents. In this chapter, we review recent progress on understanding the role of noncoding RNA in Alzheimer's disease (AD). The majority of available work has focused on miRNA, and we review the many studies implicating specific miRNAs in the development of the disease. More recently, several studies have tied other RNA classes to the disorder, including long noncoding RNA, circular RNA, and Y RNAs, and we review this fascinating field as well. Finally, we explore the potential promise of these findings for future therapeutic applications.
More Related Videos
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Neural Regulation
Alzheimer's Disease: Treatment
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Parkinson's Disease: Overview
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...